In an announcement full of surprises from Novartis and GlaxoSmithKline, the sale of the Swiss company's vaccines division to Glaxo may have been the least surprising part.
written on 22.04.2014
GlaxoSmithKline pledges $7.1B to add Novartis vaccines to its leading lineup
